brobert
/
LogseqFMS
1
0
Fork 0
Code Issues Pull Requests Packages Projects Releases Wiki Activity
You cannot select more than 25 topics Topics must start with a letter or number, can include dashes ('-') and can be up to 35 characters long.
master
Branches Tags
${ item.name }
Create tag ${ searchTerm }
Create branch ${ searchTerm }
from '68f24bcbf9'
${ noResults }
LogseqFMS/pages/STOP2030___Viaje a Ghana 20...

2.7 KiB
Raw Blame History Unescape Escape

project:: STOP2030 by:: Alejandro Krolewiecki, Marina Gold, Celia Olmos, Alan Brooks date:: 2023/12

  • Entre 2023/12/10 y 2023/12/14

  • Resumen de Alejandro Krolewiecki

    • Participants:
    • To be discussed w ISGlobal and KEMRI

    • WP 2 – RDD/Dr Oduro lead from GHS

      • Dates

        • FDC – target Oct/Nov, 2024 (early dry season)
        • PZQ - Move to January/Feb 2025 (but at least 3 weeks after FDC)
        • Have FDC available after month 11 sample collection

      • Protocol

        • Protocol ideally finalized in January 2025
          • GHS will wait for detailed review until next version of the protocol
            • Dr. Oduro's team leads review from GHS side
          • Target weeks 8-19 Jan (2 weeks) for review
          • Week 22-26 Jan to incorporate comments by ISGlobal
          • ISGlobal convene virtual discussion on protocol to address emerging/outstanding comments
          • IRB Submissions
            • ISGlobal responsible for submission of documents
            • Ghana submit by 1 Feb in advance of 7 Feb 2024 deadline (5 March as backup)
              • RDD will notify of supporting documents needed for the IRB
        • Training - R&D/ISGlobal
          • Good Clinical Practice (can be GFDA or from different organization as long as not expired)
        • Reference lab
          • Samples should be run on site (Kato Katz in the schools) and others in-country (ELISA dried blood spots for Strongyloides), with a lab in Accra still to be identified.
        • Communication & Social mobilization - NTD Programme/RDD/Health Promotion/Mundo Sano
          • Frame messaging on why doing clinical trial as based on Trichuris burden – evidence for clinical trial most clear as albendazole is less effective and we have decent burden data; Reinforce messaging that will be a clinical trial, building on and using MDA architecture as much as possible
          • GHS to review external communications plan – Tuesday 19th
          • All/Mundo Sano facilitate
            • Circulate and review materials from past MDA and/or relevant trials from communications/social mobilization (GHS has already circulated)
            • Align on targeted changes for Ghana and for Kenya (meeting with Kenya scheduled for December 19th with the Comms team)
            • Consdiera how to reflect non-STH diseases also addressed by the FDC (e.g. Onchocercosis, Limphatic Filariasis, Scabies). This was consulted with the Comms team an we are not sure it is a good idea. Perhaps we can think about doing posters and material to be left to the sites after the project, but not during the study